SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Suven Life Sciences - Quaterly Results

07 Aug 2026 Evaluate
The topline for the June 2026 quarter moved up 91.00% to Rs. 35.66 millions as compared to Rs. 18.67 millions during the year-ago period.The Net Loss for the quarter ended June 2026 is Rs. -161.20 millions as compared to Net Loss of Rs. -147.78 millions of corresponding quarter ended June 2025 Operating profit Margin for the quarter ended June 2026 further decreased to -134.89% as compared to -134.10% of corresponding quarter ended June 2025


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 35.66 18.67 91.00 35.66 18.67 91.00 71.15 66.56 6.90
Other Income 75.24 5.89 1177.42 75.24 5.89 1177.42 139.10 107.26 29.68
PBIDT -134.89 -134.10 0.59 -134.89 -134.10 0.59 -490.91 -412.11 19.12
Interest 4.76 0.00 0.00 4.76 0.00 0.00 1.58 0.47 236.17
PBDT -139.65 -134.10 4.14 -139.65 -134.10 4.14 -492.49 -412.58 19.37
Depreciation 21.55 13.68 57.53 21.55 13.68 57.53 56.14 58.22 -3.57
PBT -161.20 -147.78 9.08 -161.20 -147.78 9.08 -548.63 -470.80 16.53
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -161.20 -147.78 9.08 -161.20 -147.78 9.08 -548.63 -470.80 16.53
Equity 263.99 218.07 21.06 263.99 218.07 21.06 263.72 218.07 20.93
PBIDTM(%) -378.27 -718.26 -47.34 -378.27 -718.26 -47.34 -689.96 -619.16 11.44

Suven Life Sciences Share Price

313.10 -5.70 (-1.79%)
07-Aug-2026 10:19 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1944.85
Dr. Reddys Labs. 1163.40
Cipla 1465.60
Lupin 2400.90
Zydus Lifesciences 1102.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: